Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03915405
Title KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Kyowa Kirin Pharmaceutical Development, Inc.
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

urethra transitional cell carcinoma

transitional cell carcinoma

Therapies

Avelumab + KHK2455

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Kyowa Research Site USA004 Recruiting Gilbert Arizona 85234 United States Details
Kyowa Research Site USA001 Recruiting Saint Petersburg Florida 33709 United States Details
Kyowa Research Site USA005 Recruiting Iowa City Iowa 52242 United States Details
Kyowa Research Site USA006 Recruiting Santa Fe New Mexico 87505 United States Details
Kyowa Research Site USA 009 Recruiting Houston Texas 77030 United States Details
Kyowa Research Site USA007 Recruiting Milwaukee Wisconsin 53226 United States Details
Kyowa Research Site ESP002 Recruiting Barcelona 08003 Spain Details
Kyowa Research Site ESP003 Recruiting Barcelona 08035 Spain Details
Kyowa Research Site ESP004 Recruiting Madrid 28040 Spain Details
Kyowa Research Site ESP001 Recruiting Madrid 28050 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field